DKSH starts cooperation with GlaxoSmithKline in Hong Kong

Hong Kong, May 13, 2013 - DKSH's Business Unit Healthcare, the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, has successfully signed an agreement with GlaxoSmithKline (GSK) to provide contract sales services in both private clinics and trade channel for its antibiotic product line.

DKSH's Business Unit Healthcare in Hong Kong has the largest sales team in the industry to provide sales and promotion services for clients, now including GSK.

"We look forward to a successful partnership for both companies and to help patients to gain access to quality medicine," said Sally Storey, Vice President & General Manager, GlaxoSmithKline (Hong Kong) Limited.

"We are extremely excited to provide Market Expansion Services to GSK and to supporting them with our extensive commercial capabilities," added Richard Holloway, Vice President, DKSH Healthcare, Hong Kong. "To outsource sales and distribution service as part of its product portfolio enables GSK to concentrate on its core competencies while minimizing cost. Outsourcing is a global trend and will continue to be significant when pharmaceutical companies require expert support along the value chain."

The new partnership will further strengthen DKSH's market position in Hong Kong while contributing incrementally to the Group's overall earnings and profitability over time.
About GlaxoSmithKline
GlaxoSmithKline, one of the world's leading research-based pharmaceutical companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

About DKSH
DKSH is the leading Market Expansion Services provider with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets.

Publicly listed on the SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in Zurich. With 680 business locations in 35 countries - 660 of them in Asia - and 25,900 specialized staff, DKSH generated net sales of CHF 8.8 billion in 2012.

DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia. Custom-made offerings comprise registration and market entry studies as well as importation, customs clearance, marketing and sales to physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include ethical pharmaceuticals, consumer health, over-the-counter (OTC), as well as medical devices.

With 150 business locations in 13 countries and around 8,270 specialized staff, Business Unit Healthcare serves over 160,000 customers and generated net sales of around CHF 3.7 billion in 2012.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.